-
The Medical Clinics of North America Sep 1970
Review
Topics: Absorption; Bacteria; Cellulitis; Chemical Phenomena; Chemistry; Diarrhea; Endocarditis, Subacute Bacterial; Humans; Infections; Osteomyelitis; Otitis Media; Penicillin G; Penicillin V; Respiratory Tract Infections; Staphylococcus; Streptococcal Infections; Urinary Tract Infections
PubMed: 4990453
DOI: No ID Found -
Journal of the American Pharmaceutical... Apr 1977
Comparative Study
Topics: Adult; Biological Availability; Humans; Male; Middle Aged; Penicillin V
PubMed: 404349
DOI: No ID Found -
Tidsskrift For Den Norske Laegeforening... Nov 1975
Topics: Child; Drug Evaluation; Humans; Penicillin V
PubMed: 810918
DOI: No ID Found -
Lakartidningen
Review
Topics: Administration, Oral; Anti-Bacterial Agents; Child; Drug Administration Schedule; Evidence-Based Medicine; History, 20th Century; Humans; Microbial Sensitivity Tests; Otitis; Penicillin V; Pharyngitis; Sinusitis; Tonsillitis; Treatment Outcome
PubMed: 21140570
DOI: No ID Found -
Therapie Der Gegenwart Nov 1963
Topics: Ampicillin; Humans; Methicillin; Oxacillin; Penicillin G; Penicillin V; Penicillins
PubMed: 14112736
DOI: No ID Found -
Journal of Veterinary Pharmacology and... Mar 1987Phenoxymethyl penicillin (penicillin V) was administered intravenously (i.v.) and orally to pre-ruminant calves and the distribution and elimination kinetics, as well as...
Phenoxymethyl penicillin (penicillin V) was administered intravenously (i.v.) and orally to pre-ruminant calves and the distribution and elimination kinetics, as well as the oral bioavailability, were determined. After i.v. injection, the drug was distributed rapidly in the body, the elimination half-life (t1/2 beta) was 34 min and the apparent volume of distribution at steady-state (Vd ss) was 0.30 l/kg. Mean peak serum drug concentrations were directly related to the oral dose administered, i.e. 0.22 microgram/ml, 1.06 micrograms/ml and 2.14 micrograms/ml after dosing at 10, 20 and 40 mg/kg, respectively. The elimination t1/2 of the drug after oral dosing varied between 90 and 110 min, and the oral bioavailability was approximately 30% of the dose. The co-administration of phenoxymethyl penicillin and probenecid resulted in elevation and prolongation of serum drug concentration. The percentage of drug bound to serum proteins was 78.8% +/- 8.2%. Phenoxymethyl penicillin was probably inactivated and degraded in the gastrointestinal tract of 6-week-old calves fed exclusively hay, silage and concentrates as very low and erratic serum drug concentrations were measured after these calves were dosed orally with the drug at 40 mg/kg. In view of the narrow antibacterial spectrum of the drug and the relatively high dose required, it appears that phenoxymethyl penicillin can only be of limited practical value for the treatment of bacterial infections in preruminant calves.
Topics: Administration, Oral; Animals; Biological Availability; Cattle; Female; Half-Life; Injections, Intravenous; Kinetics; Male; Penicillin V; Protein Binding
PubMed: 3108520
DOI: 10.1111/j.1365-2885.1987.tb00071.x -
Nature May 1957
Topics: Penicillin V; Penicillins
PubMed: 13430729
DOI: 10.1038/179892a0 -
The American Journal of Emergency... Jan 1987
Topics: Anaphylaxis; Humans; Penicillin V
PubMed: 3101716
DOI: 10.1016/0735-6757(87)90313-5 -
Southern Medical Journal Jan 1977Two dosage regimens of penicillin V were compared in 327 patients with mild to moderately severe streptococcal pharyngitis. Patients fulfilling study criteria were... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Two dosage regimens of penicillin V were compared in 327 patients with mild to moderately severe streptococcal pharyngitis. Patients fulfilling study criteria were randomly assigned to a b.i.d. or a t.i.d. dosage schedule. Those in the b.i.d. group were given 500 mg twice daily; those in the t.i.d. group were given 250 mg three times daily. Duration of therapy was ten days for both groups. Cure was based on prompt symptomatic improvement, subsidence of clinical signs, and negative throat cultures for group A beta-hemolytic streptococci. Both dosage schedules yielded similar cure rates, indicating that with penicillin V, a b.i.d. regimen is as effective as a t.i.d. regimen in treating streptococcal pharyngitis.
Topics: Acute Disease; Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Glomerulonephritis; Humans; In Vitro Techniques; Penicillin V; Pharyngitis; Rheumatic Fever; Streptococcal Infections
PubMed: 402697
DOI: 10.1097/00007611-197701000-00019 -
Journal of Industrial Microbiology Apr 1991Penicillin V (phenoxymethyl penicillin) is produced by industrial strains of Penicillium chrysogenum in the presence of phenoxyacetic acid (POAc), a side-chain precursor...
Penicillin V (phenoxymethyl penicillin) is produced by industrial strains of Penicillium chrysogenum in the presence of phenoxyacetic acid (POAc), a side-chain precursor for the penicillin V molecule. The wild-type strain of P. chrysogenum produces an undesirable penicillin byproduct, para-hydroxypenicillin V (p-OH penicillin V), in addition to penicillin V, via para-hydroxylation of POAc and subsequent incorporation of the p-OH phenoxyacetic acid into the penicillin molecule. Most of the p-OH penicillin V is produced late in cycle when the POAc concentration in the medium is nearly depleted. The level of p-OH penicillin V produced by the control strain ranges up to 10-15% of the total penicillins produced. 3-Phenoxypropionic acid and p-bromophenylacetic acid partially inhibit the formation of p-OH penicillin V with a minimal effect on penicillin V productivity. Mutants deficient in their ability to hydroxylate POAc were found to produce lower levels of p-OH penicillin V. Multi-step mutation and screening, starting with the wild-type strain, have culminated in isolation of mutants which produce p-OH penicillin V as 1% of the total penicillins with no adverse effect on penicillin V productivity.
Topics: Fermentation; Hydroxylation; Kinetics; Mutagenesis; Penicillin V; Penicillium chrysogenum; Phenoxyacetates; Phenylacetates; Ultraviolet Rays
PubMed: 1367508
DOI: 10.1007/BF01575880